MicroRNA-31 regulates T-cell metabolism via HIF1α and promotes chronic GVHD pathogenesis in mice

Yongxia Wu,Corey Mealer,Steven Schutt,Carole L. Wilson,David Bastian,M. Hanief Sofi,Mengmeng Zhang,Zhenwu Luo,Hee-Jin Choi,Kaipo Yang,Linlu Tian,Hung Nguyen,Kris Helke,Lynn M. Schnapp,Honglin Wang,Xue-Zhong Yu,Steven Douglas Schutt,M.Hanief Hanief Sofi
DOI: https://doi.org/10.1182/bloodadvances.2021005103
IF: 7.642
2022-01-24
Blood Advances
Abstract:Chronic graft-versus-host disease (cGVHD) remains a major obstacle impeding successful allogeneic hematopoietic cell transplantation (allo-HCT). MicroRNAs (miRs) play key roles in immune regulation during acute GVHD development. Preclinical studies to identify miRs that impact cGVHD pathogenesis are required to develop these as potential life-saving interventions. Using oligonucleotide array, we identified miR-31 that was significantly elevated in allogeneic T cells following HCT in mice. Using genetic and pharmacological approaches, we demonstrated a key role for miR-31 in mediating donor T-cell pathogenicity in cGVHD. Recipients of miR-31-deficient T cells displayed improved cutaneous and pulmonary cGVHD. Deficiency of miR-31 reduced T-cell expansion and Th17 differentiation, but increased generation and function of Tregs. MiR-31 facilitated Neuropilin-1 down-regulation, Foxp3 loss and IFNγ production in alloantigen-induced Tregs. Mechanistically, miR-31 was required for Hypoxia-inducible Factor 1α (HIF1α) upregulation in allogeneic T cells. Hence, miR-31-deficient CD4 T cells displayed impaired activation, survival, Th17 differentiation and glycolytic metabolism under hypoxia. Upregulation of Factor Inhibiting HIF1 (FIH1), a direct target of miR-31, in miR-31-deficient T cells was essential for attenuating T-cell pathogenicity. However, miR-31-deficienty CD8 T cells maintained intact glucose metabolism, cytolytic activity and graft-versus-leukemia response. Importantly, systemic administration of a specific inhibitor of miR-31 effectively reduced donor T-cell expansion, improved Treg generation, and attenuated cGVHD. Taken together, miR-31 is a key driver for T-cell pathogenicity in cGVHD but not for the anti-leukemia activity. Taken together, miR-31 is essential to drive cGVHD pathogenesis and represents a novel potential therapeutic target for controlling cGVHD.
hematology
What problem does this paper attempt to address?